Milestone reached – the ImmunoSep study has now recruited the 200th patient

The key to success in the ImmunoSep project is its clinical study and thus the recruitment of patients. The study is set up as a randomised controlled trial of immunotherapy in five European countries, namely Greece, The Netherlands, Germany, Switzerland and Romania. After initial challenges due to the COVID-19 pandemic, recruitment picked up speed during the last year and the ImmunoSep partners are happy to have reached an important milestone recently: out of 522 patients screened for eligibility 202 patients have now been recruited to participate. The overall target of the study is to recruit 280 patients with sepsis. The study aims to test the feasibility of a personalised immunotherapy approach in patients with sepsis guided by host response biomarkers. It also sets out to assess whether personalised immunotherapies, able to revert either Macrophage activation-like syndrome (MALS) or immunoparalysis, have a beneficial impact on the outcome of patients with sepsis.

Read more about the study on: https://immunosep.eu/clinical-study